S 26948, >=98% (HPLC)

Not available outside of the UK & Ireland.

Biochem/physiol Actions

S 26948 belongs to the non-thiazolidinedione (TZD) class of drugs. It has the potential to treat diabetes and atherogenesis.

S 26948 is a selective PPARγ modulator (SPPARγM). S 26948 is as effective as rosiglitazone in reducing insulin resistance and lipid homeostasis, but does not increase body or white adipose tissue weight. S 26948 also leads to different co-activatior recruitment to PPARγ than rosiglitazone.

Features and Benefits

This compound is featured on the Nuclear Receptors (Non-Steroids) and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle